ACUR Stock Chart & Stats
$0.01
>-$0.01(-94.29%)
At close: 4:00 PM EST
$0.01
>-$0.01(-94.29%)
Day’s Range― - ―
52-Week Range<$0.01 - $0.02
Previous CloseN/A
Volume52.13K
Average Volume (3M)260.00
Market Cap
$59.40K
Enterprise Value$161.40K
Total Cash (Recent Filing)$65.00K
Total Debt (Recent Filing)$200.00K
Price to Earnings (P/E)―
Beta-17.56
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding66,001,785
10 Day Avg. Volume100
30 Day Avg. Volume260
Financial Highlights & Ratios
PEG Ratio0.50
Price to Book (P/B)123.46
Price to Sales (P/S)14.06
P/FCF Ratio-29.62
Enterprise Value/Market Cap2.72
Enterprise Value/Revenue0.10
Enterprise Value/Gross Profit0.16
Enterprise Value/Ebitda-0.27
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Acura Pharmaceuticals News
ACUR FAQ
What was Acura Pharmaceuticals’s price range in the past 12 months?
Acura Pharmaceuticals lowest stock price was <$0.01 and its highest was $0.02 in the past 12 months.
What is Acura Pharmaceuticals’s market cap?
Acura Pharmaceuticals’s market cap is $59.40K.
When is Acura Pharmaceuticals’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Acura Pharmaceuticals’s earnings last quarter?
Currently, no data Available
Is Acura Pharmaceuticals overvalued?
According to Wall Street analysts Acura Pharmaceuticals’s price is currently Overvalued.
Does Acura Pharmaceuticals pay dividends?
Acura Pharmaceuticals does not currently pay dividends.
What is Acura Pharmaceuticals’s EPS estimate?
Acura Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Acura Pharmaceuticals have?
Acura Pharmaceuticals has 66,001,785 shares outstanding.
What happened to Acura Pharmaceuticals’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Acura Pharmaceuticals?
Currently, no hedge funds are holding shares in ACUR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Acura Pharmaceuticals
Acura Pharmaceuticals, Inc. operates as a drug delivery innovator, dedicated to exploring, developing, and bringing to market novel technologies and products aimed at enhancing medication safety across the United States. Its product portfolio features Oxaydo tablets, a potent Schedule II narcotic prescribed for managing both acute and chronic moderate-to-severe pain. The company also offers the Nexafed line, consisting of pseudoephedrine and acetaminophen tablets, widely utilized as nasal decongestants in a range of over-the-counter and prescription formulations for cold, sinus, and allergy relief. Beyond its current offerings, Acura is actively advancing six additional opioid products through various stages of formulation development. To support its global reach, Acura Pharmaceuticals maintains strategic collaboration and licensing agreements with Egalet US, Inc. and Egalet Ltd. for the worldwide production and commercialization of its Oxaydo products. Furthermore, it has established a development and commercialization partnership with Abuse Deterrent Pharma, LLC to create LTX-03, an immediate-release tablet leveraging the proprietary LIMITx technology. Established in 1935, the company's operations are headquartered in Palatine, Illinois.
Technical Analysis
China Pharma Holdings
―
―
RedHill Biopharma
―
Cumberland Pharmaceuticals
―
PainReform
―
Ownership Overview
5.72% Insiders
<0.01% Other Institutional Investors
94.28% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---








